A Phase II trial of savolitinib in combination with Tagrisso® in Non Small Cell Lung Cancer patients.
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2017
At a glance
- Drugs Osimertinib (Primary) ; Savolitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 15 Mar 2017 Results from this trial will be presented at a scientific event in 2017, according to a Hutchison MediPharma media release.
- 27 Sep 2016 New trial record